|3Rodeo||United States, Los Angeles|
|Generator Ventures||United States, Redwood City|
|Array Ventures||United States, San Francisco|
|AIB Seed Capital Fund||Ireland, Dublin|
|Ambit Pragma Ventures||India, Mumbai|
|The Halo Group||United States, New York|
|BioLife Solutions||United States, Bothell|
|Seed Capital Bizkaia||Spain, Bilbao|
|Narbona Hill Corp.||United States, San Francisco|
|AT Capital Group||Russia, Moscow|
|Cyberport Macro Fund (CMF)||-|
|Electronic Soul Ventures||China, Hangzhou|
|TD Asset Management||Canada, Toronto|
|ChineseAll Digital Publishing||China, Beijing|
|iloom||South Korea, Seoul|
|$12M||27 Aug 2021||India, Gurugram|
|$6M||26 Aug 2021||Singapore, Singapore|
|$33M||23 Aug 2021||India, Bengaluru|
|$21M||19 Aug 2021||India, " India"}|
|$17M||16 Aug 2021||India, Bengaluru|
|$160M||31 Jul 2021||India, Gurugram|
|$144M||08 Jul 2021||India, Bengaluru|
|$102M||25 Apr 2021||India, New Delhi|
|$9M||26 Feb 2021||Indonesia, Jakarta|
– Ultrahuman, a Bengaluru, India-based healthtech wearable glucose tracker, raised $17.5m in Series B funding.
– The round was led by Alpha Wave Incubation (AWI), Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, as well as Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra and Roman Saini.
– The company intends to use the funds for geographical expansion and improvement of its biomarker technology.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.